{
    "clinical_study": {
        "@rank": "13162", 
        "acronym": "NUC-3", 
        "arm_group": [
            {
                "arm_group_label": "B", 
                "arm_group_type": "Experimental", 
                "description": "norUDCA"
            }, 
            {
                "arm_group_label": "C", 
                "arm_group_type": "Experimental", 
                "description": "norUDCA"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "norUDCA"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluation of the efficacy of different doses of nor UDCA vs. placebo for the treatment of\n      Primary Sclerosing Cholangitis (PSC). Identification of optimal dose(s)for the treatment of\n      PSC."
        }, 
        "brief_title": "Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Sclerosing Cholangitis", 
        "condition_browse": {
            "mesh_term": [
                "Cholangitis", 
                "Cholangitis, Sclerosing"
            ]
        }, 
        "detailed_description": {
            "textblock": "Double-blind, randomized, multi-center, placebo-controlled, comparative exploratory phase\n      II-finding trial.The study will be conducted with four treatment groups in the form of a\n      parallel-group comparison and will serve to compare oral treatment with either 500 mg/d,\n      1000 mg/d or 1500 mg/d norursodeoxycholic acid capsules vs. Placebo capsules for the\n      treatment of PSC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed Informed Consent\n\n          2. Verified diagnosis of PSC\n\n          3. PSC patients with or without IBD\n\n          4. Women of childbearing potential have to apply during the entire duration of the study\n             a highly effective method of birth control.\n\n        Exclusion Criteria:\n\n          1. History or presence of other concomitant liver diseases\n\n          2. Treatment with UDCA within 8 weeks prior to baseline visit.\n\n          3. Child B/C liver cirrhosis\n\n          4. Total bilirubin > 3.0 mg/dl at screening or baseline.\n\n          5. Any relevant systemic disease\n\n          6. TSH>ULN at screening\n\n          7. any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder\n\n          8. Any active malignant disease\n\n          9. Known intolerance/hypersensitivity to study drug\n\n         10. Existing or intended pregnancy of brest feeding\n\n         11. Simultaneous participation in another clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755507", 
            "org_study_id": "NUC-3/PSC"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "B", 
                    "C", 
                    "A"
                ], 
                "description": "Comparison of different dosages of norUDCA acid administered orally.", 
                "intervention_name": "norUDCA", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "PSC", 
        "lastchanged_date": "September 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1090"
                    }, 
                    "name": "Prof. M. Trauner"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "30623"
                    }, 
                    "name": "Prof. Michael Manns"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "0424"
                    }, 
                    "name": "Kirsten Boberg"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany", 
                "Norway"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Double-blind,Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis", 
        "other_outcome": {
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "overall_contact": {
            "email": "proels@drfalkpharma.de", 
            "last_name": "Markus Proels, PhD", 
            "phone": "+49-7611514", 
            "phone_ext": "199"
        }, 
        "overall_official": [
            {
                "affiliation": "Med. Uni Wien", 
                "last_name": "Michael Trauner, Prof", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Med. Hochschule Hannover", 
                "last_name": "Michael P Manns, Prof", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Norway: Norwegian Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in serum AP levels during treatment", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755507"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Proportion of patients with at least 50% reduction in s-ALP", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Dr. Falk Pharma GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dr. Falk Pharma GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}